For many years it was widely believed post-stroke survivors with aphasia would essentially plateau six months into their recovery. In an effort to test this assumption and support the community of adults with chronic aphasia, we studied the effectiveness of our speech-generating devices in the recovery and improvement of speech for adults with aphasia long after onset. Our research proved that adults can improve significantly beyond six months with the help of a speech device.
With the advent of telemedicine and increasing popularity around teletherapy, we set out to demonstrate, once again, that non-traditional methods like teletherapy can help adults with aphasia improve.
Working with our partners at the Synder Center for Aphasia Life Enhancement (SCALE) in Baltimore, Md., we decided to determine whether teletherapy delivered in two forms—live and automated—would be an effective treatment option for adults with chronic speech conditions. We defined “live teletherapy” as a patient working with a speech-language pathologist and “automated teletherapy” as a patient interacting with an automated therapy service. Our study with SCALE is the first clinical outcome study to combine these two types of therapy together.
Our team structured the study to include nine participants with long post-onset aphasia. Every week for 12 weeks, the participants engaged in live teletherapy with a clinician located more than 1,000 miles away in Winnipeg, Manitoba. For 12 weeks, the participants received 18 live group therapy sessions and three one-on-one live sessions. In addition to the live therapy, participants used automated therapy with Lingraphica’s TalkPath Online Speech Therapy solution—both types of therapy were supervised by a certified speech-language pathologist for the entire study.